한글목차

2024년 C형 간염(HCV) 감염자 수는 추정 2,516만명으로, 2029년까지 2,584만명으로 증가할 것으로 예측됩니다.

HCV 치료에는 혁명적인 변화의 파도가 밀려와 현재는 직접 작용형 항바이러스제(DAA)가 주류가 되고 있습니다.

HCV 파이프라인에는 68개의 분자가 있으며, 1개가 등록 전, 2개가 3단계 개발 중, 4개가 2단계 개발 중입니다.

지난 10년간 HCV의 임상시험은 866건 실시되었습니다. 가장 많은 시험이 시작된 것은 2014년 196건, 그 다음으로는 2015년 183건이었습니다.

지난 10년간 북미에서는 파트너십이 주요 거래 유형이었지만 유럽에서는 인수가 가장 많았습니다. 아시아태평양과 중남미에서는 라이선스 계약이 가장 흔했습니다.

본 보고서에서는 세계 C형 간염 치료제 시장에 대한 조사 분석을 실시하고, 질병 상황, 시상한 약품 및 파이프라인 의약품의 평가, 현재와 미래경쟁 구도 등을 제공합니다.

목차

제1장 서문

제2장 주요 조사 결과

제3장 질병 상황

• 질병의 개요
• 역학의 개요
• 치료 개요

제4장 출시가 끝난 약품의 평가

• 주요 출시 끝난 약품
• 개요 : 작용기전별
• 개요 : 분자 유형별
• 제품 프로파일, 매출 예측

제5장 가격 설정과 상환 평가

• 연간 치료비
• 가격 설정과 상환까지의 시간

제6장 파이프라인 의약품 평가

• 중기-후기의 파이프라인 의약품
• 개요 : 개발 단계별
• 개요 : 작용기전별
• 개요 : 분자 유형별
• 약품 고유의 위상 전환 성공률(PTSR)과 승인 가능성(LoA)
• 치료 영역과 적응증 고유의 PTSR과 LoA

제7장 임상시험 평가

• 과거의 개요
• 개요 : 페이즈별
• 개요 : 스테이터스별
• 개요: 페이즈별(진행중/계획이 끝난 시험)
• 가상 컴포넌트에 의한 시험
• 시험의 개요 : 지역별
• 단일국/다국간 시험:지역별
• 스폰서 상위 20개사와 내역: 페이즈별
• 스폰서 상위 20사와 내역 : 스테이터스별
• 개요 : 엔드포인트 스테이터스별
• 개요: 인종/민족별
• 등록 데이터
• 시험 시설의 상위 20개국
• 세계의 주요 20개 시설
• 실현 가능성 분석 - 지리적 개요
• 실현 가능성 분석 - 벤치마크 모델

제8장 거래 상황

• 합병, 인수, 전략적 제휴:지역별
• 최근의 합병, 인수, 전략적 제휴

제9장 상업적 평가

• 주요 시장 기업

제10장 미래 시장 카탈리스트

제11장 부록

영문목차

This reports provides a data-driven overview of the current and future competitive landscape in Hepatitis C Therapeutics .

GlobalData epidemiologists estimate that there will be 25.16 million diagnosed prevalent cases of Hepatitis C (HCV) infection in 2024, which is expected to increase slightly to 25.84 million diagnosed prevalent cases by 2029.

The HCV treatment landscape has experienced successive waves of revolutionary change and is now dominated by direct-acting antivirals (DAAs).

The HCV pipeline holds 68 molecules, with one asset in the pre-registration stage, two in Phase III development, and four assets in Phase II development.

Over the past decade, 866 clinical trials have been conducted in HCV. The highest number of studies were initiated in 2014 with 196 trials, followed by 2015 with 183 trials.

Over the past decade, partnerships were the primary deal type in North America, whereas acquisitions were most frequent in Europe. In Asia-Pacific (APAC) and South and Central America, licensing agreements were the most common.

Scope

GlobalData's Hepatitis C Therapeutics: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Hepatitis C Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Hepatitis C Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Molecule Type
• 4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

• 5.1 Annual Cost of Therapy
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Mid-to-late-stage Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Mechanism of Action
• 6.4 Overview by Molecule Type
• 6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Overview of Trials by Geography
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer